Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
31/08/2026 05:25
BRIEF-CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN Aug 31 (Reuters) - CANbridge Pharmaceuticals - HY Loss RMB37.1 MLN.
- H1 revenue RMB 27.9 million
- DO NOT RECOMMEND THE PAYMENT OF AN INTERIM DIVIDEND
Recent news on CANbridge Pharmaceuticals
See all newsChina's CANbridge Pharmaceuticals H1 revenue rises on Hunterase and Livmarli strength
Brief: CANbridge Pharmaceuticals Posts HY Loss of RMB37.1 MLN
Brief: Canbridge Pharmaceuticals Says Livmarli Obtains NHIA Reimbursement Approval In Taiwan For ALGS And PFIC
Brief: Canbridge Pharmaceuticals Initiates Registration And Launch Preparations For Gaurunning In North African Market
CANbridge Pharmaceuticals jumps as WuXi Biologics buys shares